NasdaqGS:CAPRBiotechs
How Investors May Respond To Capricor Therapeutics (CAPR) Deramiocel Regulatory Uncertainty After Wider Q1 Loss
Capricor Therapeutics reported a first-quarter 2026 net loss of US$33.94 million, with basic loss per share from continuing operations of US$0.59, and also prepared to present at investor and patient conferences later in May.
Analyst commentary highlighting optimism for potential FDA approval of Deramiocel alongside fresh uncertainty over its commercialization timing and milestones has become a key focus for investors reassessing Capricor’s outlook.
We’ll now examine how the emerging...